(SHC) Sotera Health - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83601L1026

Stock: Sterilization Services, Cobalt-60 Isotope, Laboratory Testing

Total Rating 50

Risk 66

Buy Signal -0.20

Diagnostics & Research » Life Sciences Tools & Services
Age: 5.2y

Market Cap: 5,148m
Avg Trading Vol: 27.5M USD

ATR: 3.06%
Peers RS (IBD): 78.79

EPS (Earnings per Share)

EPS CAGR: -47.83%
EPS Trend: -47.1%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 7.04%
Rev. Trend: 68.1%

Last SUE: 1.14
Qual. Beats: 3

Risk 5d forecast
Volatility	36.2%
Relative Tail Risk	-8.81%

Reward TTM
Sharpe Ratio	0.69
Alpha	9.58

Character TTM
Beta	1.262
Beta Downside	1.068

Drawdowns 3y
Max DD	48.77%
CAGR/Max DD	0.04

Description: SHC Sotera Health January 11, 2026

Sotera Health Company (NASDAQ: SHC) delivers sterilization, laboratory testing, and advisory services to the global healthcare sector, operating in the United States, Canada, Europe, and other international markets.

The business is organized into three segments:

Sterigenics – provides outsourced terminal sterilization and irradiation using gamma irradiation, ethylene-oxide (EtO), and electron-beam technologies for medical devices, pharmaceuticals, food safety, and advanced-materials customers.
Nordion – supplies Cobalt-60 isotopes that power sterilization and irradiation processes and also manufactures gamma irradiation systems; the isotope is additionally used in cancer radiotherapy.
Nelson Labs – offers microbiological, analytical chemistry, and advisory testing services for medical-device and pharma manufacturers.

Key recent metrics (as of FY 2023): revenue of roughly $1.2 billion, with the Sterigenics segment contributing ~55 % of sales and showing a 4 % year-over-year growth rate driven by rising demand for single-use medical devices. EBITDA margins have hovered around 12 %, reflecting steady pricing power in a regulated environment.

Sector drivers that materially affect SHC include: (1) the global shift toward single-use and sterile medical devices, (2) tightening regulatory standards for sterilization validation, and (3) the aging population that expands both device usage and cancer treatment volumes, boosting demand for Cobalt-60-based therapies.

For a deeper quantitative look, you might explore ValueRay’s analyst portal for SHC’s forward-looking valuation metrics.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income: 55.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.56 > 1.0
NWC/Revenue: 29.16% < 20% (prev 32.85%; Δ -3.69% < -1%)
CFO/TA 0.07 > 3% & CFO 238.2m > Net Income 55.4m
Net Debt (1.98b) to EBITDA (426.7m): 4.63 < 3
Current Ratio: 2.38 > 1.5 & < 3
Outstanding Shares: last quarter (286.7m) vs 12m ago 0.41% < -2%
Gross Margin: 55.98% > 18% (prev 0.55%; Δ 5543 % > 0.5%)
Asset Turnover: 36.32% > 50% (prev 35.58%; Δ 0.73% > 0%)
Interest Coverage Ratio: 1.76 > 6 (EBITDA TTM 426.7m / Interest Expense TTM 161.6m)

Altman Z'' 0.44

A: 0.11 (Total Current Assets 577.8m - Total Current Liabilities 242.4m) / Total Assets 3.19b
B: -0.18 (Retained Earnings -566.9m / Total Assets 3.19b)
C: 0.09 (EBIT TTM 283.7m / Avg Total Assets 3.17b)
D: -0.26 (Book Value of Equity -689.6m / Total Liabilities 2.64b)
Altman-Z'' Score: 0.44 = B

Beneish M -3.04

DSRI: 1.08 (Receivables 195.2m/176.6m, Revenue 1.15b/1.12b)
GMI: 0.99 (GM 55.98% / 55.16%)
AQI: 0.96 (AQ_t 0.46 / AQ_t-1 0.49)
SGI: 1.03 (Revenue 1.15b / 1.12b)
TATA: -0.06 (NI 55.4m - CFO 238.2m) / TA 3.19b)
Beneish M-Score: -3.04 (Cap -4..+1) = AA

What is the price of SHC shares?

As of February 08, 2026, the stock is trading at USD 17.75 with a total of 1,519,515 shares traded.
Over the past week, the price has changed by -2.04%, over one month by -5.23%, over three months by +10.87% and over the past year by +28.62%.

Is SHC a buy, sell or hold?

Sotera Health has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy SHC.

StrongBuy: 3
Buy: 2
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the SHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	20.4	15.2%
Analysts Target Price	20.4	15.2%
ValueRay Target Price	19.6	10.5%

SHC Fundamental Data Overview February 01, 2026

P/E Trailing = 90.6
P/E Forward = 20.3666
P/S = 4.4749
P/B = 9.3516
P/EG = 1.6829
Revenue TTM = 1.15b USD
EBIT TTM = 283.7m USD
EBITDA TTM = 426.7m USD
Long Term Debt = 2.13b USD (from longTermDebt, last quarter)
Short Term Debt = 22.9m USD (from shortTermDebt, last quarter)
Debt = 2.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.98b USD (from netDebt column, last quarter)
Enterprise Value = 7.12b USD (5.15b + Debt 2.28b - CCE 301.0m)
Interest Coverage Ratio = 1.76 (Ebit TTM 283.7m / Interest Expense TTM 161.6m)
EV/FCF = 83.79x (Enterprise Value 7.12b / FCF TTM 85.0m)
FCF Yield = 1.19% (FCF TTM 85.0m / Enterprise Value 7.12b)
FCF Margin = 7.39% (FCF TTM 85.0m / Revenue TTM 1.15b)
Net Margin = 4.82% (Net Income TTM 55.4m / Revenue TTM 1.15b)
Gross Margin = 55.98% ((Revenue TTM 1.15b - Cost of Revenue TTM 506.4m) / Revenue TTM)
Gross Margin QoQ = 57.04% (prev 56.61%)
Tobins Q-Ratio = 2.24 (Enterprise Value 7.12b / Total Assets 3.19b)
Interest Expense / Debt = 1.72% (Interest Expense 39.1m / Debt 2.28b)
Taxrate = 33.64% (24.5m / 72.9m)
NOPAT = 188.3m (EBIT 283.7m * (1 - 33.64%))
Current Ratio = 2.38 (Total Current Assets 577.8m / Total Current Liabilities 242.4m)
Debt / Equity = 4.14 (Debt 2.28b / totalStockholderEquity, last quarter 550.5m)
Debt / EBITDA = 4.63 (Net Debt 1.98b / EBITDA 426.7m)
Debt / FCF = 23.24 (Net Debt 1.98b / FCF TTM 85.0m)
Total Stockholder Equity = 470.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.75% (Net Income 55.4m / Total Assets 3.19b)
RoE = 11.79% (Net Income TTM 55.4m / Total Stockholder Equity 470.2m)
RoCE = 10.91% (EBIT 283.7m / Capital Employed (Equity 470.2m + L.T.Debt 2.13b))
RoIC = 7.05% (NOPAT 188.3m / Invested Capital 2.67b)
WACC = 7.68% (E(5.15b)/V(7.43b) * Re(10.57%) + D(2.28b)/V(7.43b) * Rd(1.72%) * (1-Tc(0.34)))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.89%
[DCF Debug] Terminal Value 71.72% ; FCFF base≈91.7m ; Y1≈60.2m ; Y5≈27.5m
Fair Price DCF = N/A (negative equity: EV 569.7m - Net Debt 1.98b = -1.41b; debt exceeds intrinsic value)
EPS Correlation: -47.07 | EPS CAGR: -47.83% | SUE: -4.0 | # QB: 0
Revenue Correlation: 68.09 | Revenue CAGR: 7.04% | SUE: 1.14 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.17 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=0.94 | Chg30d=-0.005 | Revisions Net=+1 | Growth EPS=+12.0% | Growth Revenue=+5.8%

Additional Sources for SHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle